Tech Company Financing Transactions
Neurovance Funding Round
Neurovance, based in Cambridge, raised $5.5 million from private investors.
Transaction Overview
Company Name
Announced On
3/26/2015
Transaction Type
Venture Equity
Amount
$5,499,459
Round
Undisclosed
Investors
Proceeds Purpose
Proceeds purposes were not disclosed. SEC regulatory filing. Contact technology company for investment details, if applicable. Not an offer or solicitation for sale of securities.
Company Information
Company Status
Acquired or Merged
Industry
Biopharmaceutical
Mailing Address
43 Thorndike Street S1-3
Cambridge, MA 02141
USA
Cambridge, MA 02141
USA
Phone
Website
Email Address
Overview
Neurovance is a clinical stage neuroscience-focused company. Following development of centanafadine SR (formerly EB-1020 SR) for adult ADHD, Neurovance will develop centanafadine SR for adolescent and pediatric ADHD.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Anthony McKinney
Chief Financial Officer
Gregg Beloff
Chief Medical Officer
Ross Reife
VP - Finance
Vincent Pappafotopoulos
VP - Operations
Catherine O'Brien
Browse more venture capital transactions:
Prev: 3/26/2015: Artsy venture capital transaction
Next: 3/26/2015: Char Software venture capital transaction
Share this article
About Our Venture Capital Transactions Database
We document every notable VC transaction. All VC database entries reported here are sourced from publicly available VC deal announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs